XNASIMVT
Market cap3.45bUSD
Jan 10, Last price
23.48USD
1D
-0.63%
1Q
-22.76%
IPO
139.59%
Name
Immunovant Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
57.22%
Rev. gr., 5y
%
Revenues
0k
Net income
-259m
L+22.93%
CFO
-214m
L+13.83%
Earnings
Feb 10, 2025
Profile
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑12 | 2018‑03 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 270,440 | 209,600 | 157,265 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (270,440) | (209,600) | (157,265) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 567 | 9 | (84) | |||||
Tax Rate | ||||||||
NOPAT | (271,007) | (209,609) | (157,181) | |||||
Net income | (259,336) 22.93% | (210,960) 34.60% | (156,730) 45.89% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 472,745 | 70,500 | 129 | |||||
BB yield | -10.59% | -3.69% | -0.02% | |||||
| Debt | ||||||||
Debt current | 276 | 1,173 | 1,145 | |||||
Long-term debt | 138 | 1,267 | 3,583 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | (347) | |||||||
Net debt | (634,951) | (374,092) | (489,089) | |||||
| Cash flow | ||||||||
Cash from operating activities | (214,227) | (188,193) | (106,112) | |||||
CAPEX | (360) | (197) | (254) | |||||
Cash from investing activities | (360) | (197) | (254) | |||||
Cash from financing activities | 472,427 | 70,885 | 200,129 | |||||
FCF | (270,097) | (208,481) | (156,331) | |||||
| Balance | ||||||||
Cash | 635,365 | 376,532 | 493,817 | |||||
Long term investments | ||||||||
Excess cash | 635,365 | 376,532 | 493,817 | |||||
Stockholders' equity | (823,761) | (565,482) | (354,971) | |||||
Invested Capital | 1,441,447 | 929,196 | 827,160 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 138,100 | 123,075 | 109,679 | |||||
Price | 32.31 108.32% | 15.51 181.49% | 5.51 -65.65% | |||||
Market cap | 4,462,011 133.75% | 1,908,898 215.87% | 604,333 -57.07% | |||||
EV | 3,827,060 | 1,534,806 | 115,244 | |||||
EBITDA | (270,209) | (209,407) | (157,139) | |||||
EV/EBITDA | ||||||||
Interest | 12,482 | 655 | ||||||
Interest/NOPBT | ||||||||